BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1151 related articles for article (PubMed ID: 33407188)

  • 1. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P; Tobe K; Abe M; Elbasha EH
    BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong.
    Cheung TH; Cheng SSY; Hsu DC; Wong QW; Pavelyev A; Walia A; Saxena K; Prabhu VS
    Cost Eff Resour Alloc; 2021 Nov; 19(1):75. PubMed ID: 34801050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the cost-effectiveness of HPV vaccination for adolescent girls in Japan: A comparison of 2-valent, 4-valent, and 9-valent HPV vaccines with consideration of cross-protection.
    Choi W; Shim E
    Prev Med; 2024 Jan; 178():107743. PubMed ID: 37866695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
    Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
    J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France.
    Majed L; Bresse X; El Mouaddin N; Schmidt A; Daniels VJ; Pavelyev A; Levy-Bachelot L; Elbasha E
    Vaccine; 2021 Jan; 39(2):438-446. PubMed ID: 33261895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW; Markowitz LE; Hariri S; Ekwueme DU; Saraiya M
    Hum Vaccin Immunother; 2016 Jun; 12(6):1363-72. PubMed ID: 26890978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine.
    Zhang Z; Zhang J; Xia N; Zhao Q
    Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
    Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
    Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    Mahumud RA; Alam K; Dunn J; Gow J
    PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L; Joura E; Largeron N; Prager B; Uhart M
    BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.